CKD-702 Plus Irinotecan in Gastric Cancer

Sponsor
National Cancer Center, Korea
Study ID
NCT05750290
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.

Key Dates

Start date
Dec 1, 2022
Status verified
Feb 2023
Primary completion
Dec 31, 2024
Completion
Dec 31, 2025

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CKD-702 in combination with irinotecan

Primary Outcome Measure

Best objective response rate [ Time Frame: Through study completion, an average of 24 weeks ]

Central Contacts

Related Studies